The North American Immune Tolerance Registry

Practices, outcomes, outcome predictors

Donna M. DiMichele, B. L. Kroner, S. Adair, J. Addiego, V. Anderson, J. Barbosa, P. Blatt, P. Bockenstedt, V. Castle, P. Chenaille, J. Cohen, E. Czapek, J. Davis, G. Davignon, P. De Alarcon, R. Dubowy, J. DuCore, M. Dugdale, B. Ewenstein, J. Fahner & 51 others T. John Gribble, David J Gnarra, R. Gruppo, N. Hakami, M. Hanna, W. Hanna, P. Haut, G. Heggie, A. Homans, J. Hutter, C. Johnson, M. Kajani, M. Karpatkin, Casper Kasper, J. Katz, C. Kessler, N. Key, M. Koerper, B. Konkle, R. Kosinski, J. Lazerson, A. Lightsey, T. Loew, J. Lusher, W. MacLaughlin, M. Manco-Johnson, C. Manno, K. McRedmond, P. Phatak, J. Powell, M. Ragni, C. Rosenfield, J. Sanders, P. Santiago-Borrero, P. Saidi, R. Seeler, S. Seremetis, J. Sexauer, S. Travis, L. Valdez, E. Warner, G. White, D. Barrand, J. Drown, J. Herst, M. Inwood, D. Lillicrap, G. Rivard, S. Rubin, H. Stranczyniski, J. Teitel

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

The North American Immune Tolerance Registry was initiated to study of immune tolerance (ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for haemophilia A (HA) and B (HB) inhibitor patients; 2) therapeutic outcomes; 3) potential predictors of successful outcome and 4) complications of therapy. Data on 188 ITT courses was collected by questionnaire from 60 haemophilia centers from 1993-99. Among the completed courses, the overall ITT success rate was 70% (115/164) for all HA and 31% (5/16) for all HB. Outcome parameters noted to be predictive of ITT success for all HA were 1) pre-ITT induction (p = 0.003), 2) ITT peak (p = 0.007) and 3) historical pre ITT peak (p = 0.04) inhibitors titres. An inverse correlation between total daily dose (units/kg/day) and success: (80% with under 50; 71% with 50-99; 73% with 100-199; and 41% with ≥ 200, p = 0.01) was found. Outcome predictors were not evaluable for HB, although adverse reactions to therapy, including nephrotic syndrome, and access complications were more common among failed courses. Infection most often complicated the use of access catheters. These results are discussed within the context of the international ITT registry and upcoming prospective ITT study.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalThrombosis and Haemostasis
Volume87
Issue number1
StatePublished - Feb 5 2002

Fingerprint

Immune Tolerance
Hemophilia A
Registries
Hemophilia B
Nephrotic Syndrome
Therapeutics
Canada
Catheters
Prospective Studies
Infection

Keywords

  • Hemophilia A
  • Hemophilia B
  • Immune tolerance
  • Inhibitor therapy

ASJC Scopus subject areas

  • Hematology

Cite this

DiMichele, D. M., Kroner, B. L., Adair, S., Addiego, J., Anderson, V., Barbosa, J., ... Teitel, J. (2002). The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. Thrombosis and Haemostasis, 87(1), 52-57.

The North American Immune Tolerance Registry : Practices, outcomes, outcome predictors. / DiMichele, Donna M.; Kroner, B. L.; Adair, S.; Addiego, J.; Anderson, V.; Barbosa, J.; Blatt, P.; Bockenstedt, P.; Castle, V.; Chenaille, P.; Cohen, J.; Czapek, E.; Davis, J.; Davignon, G.; De Alarcon, P.; Dubowy, R.; DuCore, J.; Dugdale, M.; Ewenstein, B.; Fahner, J.; Gribble, T. John; Gnarra, David J; Gruppo, R.; Hakami, N.; Hanna, M.; Hanna, W.; Haut, P.; Heggie, G.; Homans, A.; Hutter, J.; Johnson, C.; Kajani, M.; Karpatkin, M.; Kasper, Casper; Katz, J.; Kessler, C.; Key, N.; Koerper, M.; Konkle, B.; Kosinski, R.; Lazerson, J.; Lightsey, A.; Loew, T.; Lusher, J.; MacLaughlin, W.; Manco-Johnson, M.; Manno, C.; McRedmond, K.; Phatak, P.; Powell, J.; Ragni, M.; Rosenfield, C.; Sanders, J.; Santiago-Borrero, P.; Saidi, P.; Seeler, R.; Seremetis, S.; Sexauer, J.; Travis, S.; Valdez, L.; Warner, E.; White, G.; Barrand, D.; Drown, J.; Herst, J.; Inwood, M.; Lillicrap, D.; Rivard, G.; Rubin, S.; Stranczyniski, H.; Teitel, J.

In: Thrombosis and Haemostasis, Vol. 87, No. 1, 05.02.2002, p. 52-57.

Research output: Contribution to journalArticle

DiMichele, DM, Kroner, BL, Adair, S, Addiego, J, Anderson, V, Barbosa, J, Blatt, P, Bockenstedt, P, Castle, V, Chenaille, P, Cohen, J, Czapek, E, Davis, J, Davignon, G, De Alarcon, P, Dubowy, R, DuCore, J, Dugdale, M, Ewenstein, B, Fahner, J, Gribble, TJ, Gnarra, DJ, Gruppo, R, Hakami, N, Hanna, M, Hanna, W, Haut, P, Heggie, G, Homans, A, Hutter, J, Johnson, C, Kajani, M, Karpatkin, M, Kasper, C, Katz, J, Kessler, C, Key, N, Koerper, M, Konkle, B, Kosinski, R, Lazerson, J, Lightsey, A, Loew, T, Lusher, J, MacLaughlin, W, Manco-Johnson, M, Manno, C, McRedmond, K, Phatak, P, Powell, J, Ragni, M, Rosenfield, C, Sanders, J, Santiago-Borrero, P, Saidi, P, Seeler, R, Seremetis, S, Sexauer, J, Travis, S, Valdez, L, Warner, E, White, G, Barrand, D, Drown, J, Herst, J, Inwood, M, Lillicrap, D, Rivard, G, Rubin, S, Stranczyniski, H & Teitel, J 2002, 'The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors', Thrombosis and Haemostasis, vol. 87, no. 1, pp. 52-57.
DiMichele DM, Kroner BL, Adair S, Addiego J, Anderson V, Barbosa J et al. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. Thrombosis and Haemostasis. 2002 Feb 5;87(1):52-57.
DiMichele, Donna M. ; Kroner, B. L. ; Adair, S. ; Addiego, J. ; Anderson, V. ; Barbosa, J. ; Blatt, P. ; Bockenstedt, P. ; Castle, V. ; Chenaille, P. ; Cohen, J. ; Czapek, E. ; Davis, J. ; Davignon, G. ; De Alarcon, P. ; Dubowy, R. ; DuCore, J. ; Dugdale, M. ; Ewenstein, B. ; Fahner, J. ; Gribble, T. John ; Gnarra, David J ; Gruppo, R. ; Hakami, N. ; Hanna, M. ; Hanna, W. ; Haut, P. ; Heggie, G. ; Homans, A. ; Hutter, J. ; Johnson, C. ; Kajani, M. ; Karpatkin, M. ; Kasper, Casper ; Katz, J. ; Kessler, C. ; Key, N. ; Koerper, M. ; Konkle, B. ; Kosinski, R. ; Lazerson, J. ; Lightsey, A. ; Loew, T. ; Lusher, J. ; MacLaughlin, W. ; Manco-Johnson, M. ; Manno, C. ; McRedmond, K. ; Phatak, P. ; Powell, J. ; Ragni, M. ; Rosenfield, C. ; Sanders, J. ; Santiago-Borrero, P. ; Saidi, P. ; Seeler, R. ; Seremetis, S. ; Sexauer, J. ; Travis, S. ; Valdez, L. ; Warner, E. ; White, G. ; Barrand, D. ; Drown, J. ; Herst, J. ; Inwood, M. ; Lillicrap, D. ; Rivard, G. ; Rubin, S. ; Stranczyniski, H. ; Teitel, J. / The North American Immune Tolerance Registry : Practices, outcomes, outcome predictors. In: Thrombosis and Haemostasis. 2002 ; Vol. 87, No. 1. pp. 52-57.
@article{a7eb520defc448c4894775423e451342,
title = "The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors",
abstract = "The North American Immune Tolerance Registry was initiated to study of immune tolerance (ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for haemophilia A (HA) and B (HB) inhibitor patients; 2) therapeutic outcomes; 3) potential predictors of successful outcome and 4) complications of therapy. Data on 188 ITT courses was collected by questionnaire from 60 haemophilia centers from 1993-99. Among the completed courses, the overall ITT success rate was 70{\%} (115/164) for all HA and 31{\%} (5/16) for all HB. Outcome parameters noted to be predictive of ITT success for all HA were 1) pre-ITT induction (p = 0.003), 2) ITT peak (p = 0.007) and 3) historical pre ITT peak (p = 0.04) inhibitors titres. An inverse correlation between total daily dose (units/kg/day) and success: (80{\%} with under 50; 71{\%} with 50-99; 73{\%} with 100-199; and 41{\%} with ≥ 200, p = 0.01) was found. Outcome predictors were not evaluable for HB, although adverse reactions to therapy, including nephrotic syndrome, and access complications were more common among failed courses. Infection most often complicated the use of access catheters. These results are discussed within the context of the international ITT registry and upcoming prospective ITT study.",
keywords = "Hemophilia A, Hemophilia B, Immune tolerance, Inhibitor therapy",
author = "DiMichele, {Donna M.} and Kroner, {B. L.} and S. Adair and J. Addiego and V. Anderson and J. Barbosa and P. Blatt and P. Bockenstedt and V. Castle and P. Chenaille and J. Cohen and E. Czapek and J. Davis and G. Davignon and {De Alarcon}, P. and R. Dubowy and J. DuCore and M. Dugdale and B. Ewenstein and J. Fahner and Gribble, {T. John} and Gnarra, {David J} and R. Gruppo and N. Hakami and M. Hanna and W. Hanna and P. Haut and G. Heggie and A. Homans and J. Hutter and C. Johnson and M. Kajani and M. Karpatkin and Casper Kasper and J. Katz and C. Kessler and N. Key and M. Koerper and B. Konkle and R. Kosinski and J. Lazerson and A. Lightsey and T. Loew and J. Lusher and W. MacLaughlin and M. Manco-Johnson and C. Manno and K. McRedmond and P. Phatak and J. Powell and M. Ragni and C. Rosenfield and J. Sanders and P. Santiago-Borrero and P. Saidi and R. Seeler and S. Seremetis and J. Sexauer and S. Travis and L. Valdez and E. Warner and G. White and D. Barrand and J. Drown and J. Herst and M. Inwood and D. Lillicrap and G. Rivard and S. Rubin and H. Stranczyniski and J. Teitel",
year = "2002",
month = "2",
day = "5",
language = "English (US)",
volume = "87",
pages = "52--57",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "1",

}

TY - JOUR

T1 - The North American Immune Tolerance Registry

T2 - Practices, outcomes, outcome predictors

AU - DiMichele, Donna M.

AU - Kroner, B. L.

AU - Adair, S.

AU - Addiego, J.

AU - Anderson, V.

AU - Barbosa, J.

AU - Blatt, P.

AU - Bockenstedt, P.

AU - Castle, V.

AU - Chenaille, P.

AU - Cohen, J.

AU - Czapek, E.

AU - Davis, J.

AU - Davignon, G.

AU - De Alarcon, P.

AU - Dubowy, R.

AU - DuCore, J.

AU - Dugdale, M.

AU - Ewenstein, B.

AU - Fahner, J.

AU - Gribble, T. John

AU - Gnarra, David J

AU - Gruppo, R.

AU - Hakami, N.

AU - Hanna, M.

AU - Hanna, W.

AU - Haut, P.

AU - Heggie, G.

AU - Homans, A.

AU - Hutter, J.

AU - Johnson, C.

AU - Kajani, M.

AU - Karpatkin, M.

AU - Kasper, Casper

AU - Katz, J.

AU - Kessler, C.

AU - Key, N.

AU - Koerper, M.

AU - Konkle, B.

AU - Kosinski, R.

AU - Lazerson, J.

AU - Lightsey, A.

AU - Loew, T.

AU - Lusher, J.

AU - MacLaughlin, W.

AU - Manco-Johnson, M.

AU - Manno, C.

AU - McRedmond, K.

AU - Phatak, P.

AU - Powell, J.

AU - Ragni, M.

AU - Rosenfield, C.

AU - Sanders, J.

AU - Santiago-Borrero, P.

AU - Saidi, P.

AU - Seeler, R.

AU - Seremetis, S.

AU - Sexauer, J.

AU - Travis, S.

AU - Valdez, L.

AU - Warner, E.

AU - White, G.

AU - Barrand, D.

AU - Drown, J.

AU - Herst, J.

AU - Inwood, M.

AU - Lillicrap, D.

AU - Rivard, G.

AU - Rubin, S.

AU - Stranczyniski, H.

AU - Teitel, J.

PY - 2002/2/5

Y1 - 2002/2/5

N2 - The North American Immune Tolerance Registry was initiated to study of immune tolerance (ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for haemophilia A (HA) and B (HB) inhibitor patients; 2) therapeutic outcomes; 3) potential predictors of successful outcome and 4) complications of therapy. Data on 188 ITT courses was collected by questionnaire from 60 haemophilia centers from 1993-99. Among the completed courses, the overall ITT success rate was 70% (115/164) for all HA and 31% (5/16) for all HB. Outcome parameters noted to be predictive of ITT success for all HA were 1) pre-ITT induction (p = 0.003), 2) ITT peak (p = 0.007) and 3) historical pre ITT peak (p = 0.04) inhibitors titres. An inverse correlation between total daily dose (units/kg/day) and success: (80% with under 50; 71% with 50-99; 73% with 100-199; and 41% with ≥ 200, p = 0.01) was found. Outcome predictors were not evaluable for HB, although adverse reactions to therapy, including nephrotic syndrome, and access complications were more common among failed courses. Infection most often complicated the use of access catheters. These results are discussed within the context of the international ITT registry and upcoming prospective ITT study.

AB - The North American Immune Tolerance Registry was initiated to study of immune tolerance (ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for haemophilia A (HA) and B (HB) inhibitor patients; 2) therapeutic outcomes; 3) potential predictors of successful outcome and 4) complications of therapy. Data on 188 ITT courses was collected by questionnaire from 60 haemophilia centers from 1993-99. Among the completed courses, the overall ITT success rate was 70% (115/164) for all HA and 31% (5/16) for all HB. Outcome parameters noted to be predictive of ITT success for all HA were 1) pre-ITT induction (p = 0.003), 2) ITT peak (p = 0.007) and 3) historical pre ITT peak (p = 0.04) inhibitors titres. An inverse correlation between total daily dose (units/kg/day) and success: (80% with under 50; 71% with 50-99; 73% with 100-199; and 41% with ≥ 200, p = 0.01) was found. Outcome predictors were not evaluable for HB, although adverse reactions to therapy, including nephrotic syndrome, and access complications were more common among failed courses. Infection most often complicated the use of access catheters. These results are discussed within the context of the international ITT registry and upcoming prospective ITT study.

KW - Hemophilia A

KW - Hemophilia B

KW - Immune tolerance

KW - Inhibitor therapy

UR - http://www.scopus.com/inward/record.url?scp=0036147943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036147943&partnerID=8YFLogxK

M3 - Article

VL - 87

SP - 52

EP - 57

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 1

ER -